Darunavir/Cobicistat + Elvitegravir = Unknown or no reaction

Effect on Concentration

Darunavir/Cobicistat
No change
Applies within class?
No
Elvitegravir
No change
Applies within class?
No

Pharmacologic Effects

Darunavir/Cobicistat
Effect
N/A
Applies within class?
No
Elvitegravir
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 22-Nov-2022

Summary

There is no long-term safety data on cobicistat BID

Sources

Darunavir/cobicistat vs elvitegravir or etravirine ^

Study Design

This was a pharmacokinetic (PK) study in healthy volunteers. After subjects recieved darunavir/ritonavir (DRV/r 600/100mg) twice daily (BID), a seven-day washout, then (DRV/cobicistat 600/150mg) BID. The group was split into two subsets (n=12 in each) and randomized to DRV/cobicistat 600/150mg BID plus elvitegravir (EVG) 150mg daily or etravirine. All study treatments were adminstered for 10 days. DRV exposure was assessed using geometric mean ratios, with 90% confidence interval (CI) bounds of 80-125% and EVG PK was compared against historial data.

Study Results

Coadministration of EVG did not affect DRV PK or EVG PK.

Study Conclusions

References

S Ramanathan, H Wang, J Szwarcberg, BP Kearney. Safety/tolerability, pharmacokinetics and boosting of twice-daily cobicistat administered alone or in combination with darunavir or tipranavir [poster p08]. 13th International Workshop On Clinical Pharmacology Of Hiv Therapy. Barcelona, Spain. ; 2012.